Hsbc Holdings PLC Sells 22,118 Shares of Progyny, Inc. $PGNY

Hsbc Holdings PLC reduced its stake in Progyny, Inc. (NASDAQ:PGNY) by 53.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,206 shares of the company’s stock after selling 22,118 shares during the period. Hsbc Holdings PLC’s holdings in Progyny were worth $327,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. California State Teachers Retirement System boosted its holdings in shares of Progyny by 0.7% in the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after purchasing an additional 457 shares during the period. Teza Capital Management LLC increased its holdings in Progyny by 5.4% during the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock worth $221,000 after purchasing an additional 516 shares during the period. Aristides Capital LLC raised its position in Progyny by 4.6% during the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after purchasing an additional 528 shares in the last quarter. Oxford Asset Management LLP raised its position in Progyny by 4.3% during the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after purchasing an additional 531 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Progyny by 3.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 19,202 shares of the company’s stock worth $493,000 after buying an additional 637 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Progyny

In other Progyny news, insider Geoffrey Clapp sold 1,530 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $25.58, for a total transaction of $39,137.40. Following the completion of the sale, the insider directly owned 59,117 shares of the company’s stock, valued at approximately $1,512,212.86. This represents a 2.52% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Mark S. Livingston sold 2,517 shares of the stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the sale, the chief financial officer directly owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. The trade was a 3.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 36,916 shares of company stock valued at $939,875 over the last 90 days. Company insiders own 9.90% of the company’s stock.

Progyny Price Performance

Progyny stock opened at $31.13 on Monday. The firm has a market cap of $2.44 billion, a P/E ratio of 40.43, a P/E/G ratio of 2.47 and a beta of 1.01. The business has a fifty day moving average of $28.55 and a two-hundred day moving average of $23.22. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $33.06.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.24. The business had revenue of $328.50 million for the quarter, compared to the consensus estimate of $326.46 million. Progyny had a return on equity of 13.34% and a net margin of 5.23%.The business’s revenue was down 26.4% compared to the same quarter last year. During the same period last year, the business posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities analysts expect that Progyny, Inc. will post 1.19 earnings per share for the current year.

Progyny announced that its board has approved a share buyback plan on Tuesday, May 26th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the company to reacquire up to 10.3% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Analyst Ratings Changes

PGNY has been the topic of a number of recent research reports. KeyCorp increased their price target on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Citizens Jmp lifted their price objective on Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a report on Monday, May 11th. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 8th. Citigroup reiterated an “outperform” rating on shares of Progyny in a report on Monday, May 11th. Finally, Truist Financial raised their target price on shares of Progyny from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.25.

Progyny Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.